Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 4/2019

23.05.2019 | ORIGINAL ARTICLE

Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease

verfasst von: Efstratios Koutroumpakis, Elvira O. Gosmanova, Heather Stahura, Stephanie Jou, Rabah Alreshq, Ashar Ata, Mandeep S. Sidhu, Edward Philbin, William E. Boden, Radmila Lyubarova

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Stable ischemic heart disease (SIHD) is prevalent in patients with chronic kidney disease (CKD); however, whether guideline-directed medical therapy (GDMT) is adequately implemented in patients with SIHD and CKD is unknown.

Hypothesis

Use of GDMT and achievement of treatment targets would be higher in SIHD patients without CKD than in patients with CKD.

Methods

This was a retrospective study of 563 consecutive patients with SIHD (mean age 67.8 years, 84% Caucasians, 40% females). CKD was defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73m2 using the four-variable MDRD Study equation. We examined the likelihood of achieving GDMT targets (prescription of high-intensity statins, antiplatelet agents, renin-angiotensin-aldosterone system inhibitors (RAASi), and low-density lipoprotein cholesterol levels < 70 mg/dL, blood pressure < 140/90 mmHg, and hemoglobin A1C < 7% if diabetes) in patients with (n = 166) and without CKD (n = 397).

Results

Compared with the non-CKD group, CKD patients were significantly older (72 vs 66 years; p < 0.001), more commonly female (49 vs 36%; p = 0.002), had a higher prevalence of diabetes (46 vs 34%; p = 0.004), and left ventricular systolic ejection fraction (LVEF) < 40% (23 vs. 10%, p < 0.001). All GDMT goals were achieved in 26% and 24% of patients with and without CKD, respectively (p = 0.712). There were no between-group differences in achieving individual GDMT goals with the exception of RAASi (CKD vs non-CKD: adjusted risk ratio 0.73, 95% CI 0.62–0.87; p < 0.001).

Conclusions

Attainment of GDMT goals in SIHD patients with CKD was similar to patients without CKD, with the exception of lower rates of RAASi use in the CKD group.
Literatur
1.
Zurück zum Zitat Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.CrossRefPubMed Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.CrossRefPubMed
2.
Zurück zum Zitat Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.CrossRefPubMed Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.CrossRefPubMed
3.
Zurück zum Zitat Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91:797–807.CrossRefPubMed Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91:797–807.CrossRefPubMed
4.
Zurück zum Zitat Mathew RO, Bangalore S, Sidhu MS, Fleg JL, Maddux FW. Increasing inclusion of patients with advanced chronic kidney disease in cardiovascular clinical trials. Kidney Int. 2018;93:787–8.CrossRefPubMed Mathew RO, Bangalore S, Sidhu MS, Fleg JL, Maddux FW. Increasing inclusion of patients with advanced chronic kidney disease in cardiovascular clinical trials. Kidney Int. 2018;93:787–8.CrossRefPubMed
5.
Zurück zum Zitat Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessel. 2014;29:21–8.CrossRef Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessel. 2014;29:21–8.CrossRef
6.
Zurück zum Zitat Farkouh ME, Sidhu MS, Brooks MM, Vlachos H, Boden WE, Frye RL, et al. Impact of chronic kidney disease on outcomes of myocardial revascularization in patients with diabetes. J Am Coll Cardiol. 2019;73:400–11.CrossRefPubMed Farkouh ME, Sidhu MS, Brooks MM, Vlachos H, Boden WE, Frye RL, et al. Impact of chronic kidney disease on outcomes of myocardial revascularization in patients with diabetes. J Am Coll Cardiol. 2019;73:400–11.CrossRefPubMed
7.
Zurück zum Zitat Marenzi G, Cosentino N, Guastoni C. How to balance risks and benefits in the management of CKD patients with coronary artery disease. J Nephrol. 2015;28:403–13.CrossRefPubMed Marenzi G, Cosentino N, Guastoni C. How to balance risks and benefits in the management of CKD patients with coronary artery disease. J Nephrol. 2015;28:403–13.CrossRefPubMed
8.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.CrossRefPubMed
9.
Zurück zum Zitat Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–e164.CrossRefPubMed Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–e164.CrossRefPubMed
10.
Zurück zum Zitat Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRefPubMed Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRefPubMed
11.
Zurück zum Zitat Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71:A7.CrossRefPubMedPubMedCentral Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71:A7.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GF: Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013;Feb 28;(2):CD008834. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GF: Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013;Feb 28;(2):CD008834.
13.
Zurück zum Zitat Agrawal H, Aggarwal K, Littrell R, Velagapudi P, Turagam MK, Mittal M, et al. Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease. Curr Cardiol Rev. 2015;11:261–9.CrossRefPubMedPubMedCentral Agrawal H, Aggarwal K, Littrell R, Velagapudi P, Turagam MK, Mittal M, et al. Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease. Curr Cardiol Rev. 2015;11:261–9.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kalra PR, Garcia-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, et al. Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. PLoS One. 2014;9:e102335.CrossRefPubMedPubMedCentral Kalra PR, Garcia-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, et al. Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. PLoS One. 2014;9:e102335.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Lahoz C, Mostaza JM, Mantilla MT, Taboada M, Tranche S, Lopez-Rodriguez I, et al. Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. Am J Cardiol. 2008;101:1098–102.CrossRefPubMed Lahoz C, Mostaza JM, Mantilla MT, Taboada M, Tranche S, Lopez-Rodriguez I, et al. Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. Am J Cardiol. 2008;101:1098–102.CrossRefPubMed
16.
Zurück zum Zitat Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.CrossRefPubMed Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.CrossRefPubMed
17.
Zurück zum Zitat Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.CrossRefPubMedPubMedCentral Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.CrossRefPubMed Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.CrossRefPubMed
19.
Zurück zum Zitat Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.CrossRefPubMed Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.CrossRefPubMed
20.
Zurück zum Zitat Streja E, Gosmanova EO, Molnar MZ, Soohoo M, Moradi H, Potukuchi PK, et al. Association of continuation of statin therapy initiated before transition to chronic dialysis therapy with mortality after dialysis initiation. JAMA Netw Open. 2018;1:e182311.CrossRefPubMedPubMedCentral Streja E, Gosmanova EO, Molnar MZ, Soohoo M, Moradi H, Potukuchi PK, et al. Association of continuation of statin therapy initiated before transition to chronic dialysis therapy with mortality after dialysis initiation. JAMA Netw Open. 2018;1:e182311.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Hoffman E, et al. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013;126:693–700.e691.CrossRefPubMed Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Hoffman E, et al. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013;126:693–700.e691.CrossRefPubMed
22.
Zurück zum Zitat Cordero A, Rodriguez Padial L, Batalla A, Lopez Barreiro L, Torres Calvo F, Castellano JM, Ruiz E, Bertomeu-Martinez V. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: results from the CAPS study. Cardiovasc Ther 2017;35(2). Cordero A, Rodriguez Padial L, Batalla A, Lopez Barreiro L, Torres Calvo F, Castellano JM, Ruiz E, Bertomeu-Martinez V. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: results from the CAPS study. Cardiovasc Ther 2017;35(2).
23.
Zurück zum Zitat Morrison FJ, Zhang H, Skentzos S, Shubina M, Bentley-Lewis R, Turchin A. Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease. Cardiorenal Med. 2014;4:225–33.CrossRefPubMedPubMedCentral Morrison FJ, Zhang H, Skentzos S, Shubina M, Bentley-Lewis R, Turchin A. Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease. Cardiorenal Med. 2014;4:225–33.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Huang H, Zeng C, Ma Y, Chen Y, Chen C, Liu C, et al. Effects of long-term statin therapy in coronary artery disease patients with or without chronic kidney disease. Dis Markers. 2015;2015:252564.PubMedPubMedCentral Huang H, Zeng C, Ma Y, Chen Y, Chen C, Liu C, et al. Effects of long-term statin therapy in coronary artery disease patients with or without chronic kidney disease. Dis Markers. 2015;2015:252564.PubMedPubMedCentral
25.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–248.CrossRefPubMed Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–248.CrossRefPubMed
26.
Zurück zum Zitat Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342–51.CrossRefPubMed Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342–51.CrossRefPubMed
27.
Zurück zum Zitat James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefPubMed James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefPubMed
28.
Zurück zum Zitat Banegas JR, Vegazo O, Serrano P, Luengo E, Mantilla T, Fernandez R, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis. 2006;188:420–4.CrossRefPubMed Banegas JR, Vegazo O, Serrano P, Luengo E, Mantilla T, Fernandez R, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis. 2006;188:420–4.CrossRefPubMed
29.
Zurück zum Zitat Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, et al. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology. 2005;56:731–41.CrossRefPubMed Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, et al. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology. 2005;56:731–41.CrossRefPubMed
30.
Zurück zum Zitat Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation. 2005;111:488–93.CrossRefPubMed Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation. 2005;111:488–93.CrossRefPubMed
31.
Zurück zum Zitat Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–67.CrossRefPubMed Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–67.CrossRefPubMed
32.
Zurück zum Zitat Brown TM, Voeks JH, Bittner V, Brenner DA, Cushman M, Goff DC Jr, et al. Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS study (REasons for geographic and racial differences in stroke). J Am Coll Cardiol. 2014;63:1626–33.CrossRefPubMedPubMedCentral Brown TM, Voeks JH, Bittner V, Brenner DA, Cushman M, Goff DC Jr, et al. Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS study (REasons for geographic and racial differences in stroke). J Am Coll Cardiol. 2014;63:1626–33.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRefPubMed Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRefPubMed
34.
Zurück zum Zitat Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.CrossRefPubMed Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.CrossRefPubMed
Metadaten
Titel
Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease
verfasst von
Efstratios Koutroumpakis
Elvira O. Gosmanova
Heather Stahura
Stephanie Jou
Rabah Alreshq
Ashar Ata
Mandeep S. Sidhu
Edward Philbin
William E. Boden
Radmila Lyubarova
Publikationsdatum
23.05.2019
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2019
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-019-06883-z

Weitere Artikel der Ausgabe 4/2019

Cardiovascular Drugs and Therapy 4/2019 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.